Priliximab
Priliximab
Priliximab (pronounced: pri-lixi-mab) is a type of monoclonal antibody used in the treatment of various autoimmune diseases and cancers.
Etymology
The term "Priliximab" is derived from the International Nonproprietary Names (INN), where 'pr' signifies the drug's use in autoimmune diseases, 'lix' indicates the drug's human origin, 'i' denotes the immune system as the target, and 'mab' is the suffix for monoclonal antibodies.
Usage
Priliximab is used in the treatment of diseases where the immune system is overactive or where it attacks the body's own cells. This includes conditions such as rheumatoid arthritis, lupus, and certain types of cancer. It works by binding to specific proteins in the body, blocking their action and reducing inflammation or preventing the growth of cancer cells.
Related Terms
- Monoclonal Antibodies: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells.
- Autoimmune Diseases: Conditions in which your immune system mistakenly attacks your body.
- Rheumatoid Arthritis: A chronic inflammatory disorder affecting many joints, including those in the hands and feet.
- Lupus: An inflammatory disease caused when the immune system attacks its own tissues.
- Cancer: A group of diseases characterized by the uncontrolled growth and spread of abnormal cells.
External links
- Medical encyclopedia article on Priliximab
- Wikipedia's article - Priliximab
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski